Visão geral da empresa
A clinical-stage biotechnology company, CEL-SCI Corporation focuses its research and development efforts on treating cancer and other diseases by leveraging the body's immune system within the United States. The firm operates within the broader healthcare sector, specifically functioning in the biotechnology industry, which is characterized by high capital requirements and significant regulatory hurdles for product approval. The company's current market capitalization stands at $36.20M, while its annual revenue for the trailing twelve months is not available in public filings, and its employee count is listed as not applicable. These valuation and scale metrics indicate that CEL-SCI Corporation operates as a small-cap entity with a limited revenue footprint, suggesting it is likely in an early development stage or generating revenue through non-traditional channels that are not fully captured in standard reporting. The absence of listed employee data further points to a lean operational structure typical of companies prioritizing R&D expenditures over large-scale infrastructure deployment at this stage of their lifecycle.
Saúde financeira
The company reports a net income of $-23,807,440 for the trailing twelve months, while EBITDA is recorded at $-21,230,740, and revenue for the same period is not available. The substantial gap between the reported net income loss and the EBITDA figure reveals a significant cost structure burden driven by non-operating expenses, such as interest costs, which are deducted after calculating operating earnings but before arriving at the final net income. Free cash flow stands at $-8,943,390, indicating that the company is burning cash to fund its operations and research initiatives, which limits its immediate financial flexibility but is consistent with the profile of a development-stage biotech firm. All three reported margins—gross margin, operating margin, and profit margin—are stated as 0.0%, a figure that typically indicates either a lack of historical sales data in the reporting period or a specific accounting treatment where revenues do not yet offset the massive costs of drug development. On the balance sheet, the company holds $6.28M in cash against total debt of $9.11M, resulting in a debt-to-equity ratio of 81.75, which suggests a highly leveraged position relative to its equity base. The current ratio is 1.40, indicating that the company possesses 1.40 units of current assets for every single unit of current liabilities, which suggests a moderate level of short-term liquidity sufficient to meet obligations as they come due. Return on Equity is -212.1% and Return on Assets is -59.9%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, reflecting the early-stage nature of the assets and the intense costs associated with bringing immunotherapy products like Multikine to market.
Avaliação de valorização
The trailing twelve-month P/E ratio is not available due to the lack of positive net income, while the forward P/E ratio is listed as -4.65, implying that analysts or the market expects earnings to remain negative in the near term. The price-to-book ratio is 3.09, indicating that the market values the company's equity at more than three times its book value, a premium often seen in biotechnology firms where intangible assets like intellectual property and pipeline potential are not fully reflected on the balance sheet. The price-to-sales ratio is not available, and the EV/EBITDA multiple is -1.76, suggesting that valuation is currently being assessed on a pre-profit basis where enterprise value is only slightly negative relative to operating cash generation. The stock has traded within a 52-week range between a low of $1.98 and a high of $13.48, and based on the available price metrics, the current trading price is situated significantly below the 52-week high, reflecting market volatility and the high-risk premium associated with clinical-stage assets. The beta value is 1.00, meaning the stock's price volatility historically moves in tandem with the broader market, lacking the amplified volatility often seen in small-cap biotechnology stocks with higher beta coefficients.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, indicating that the firm does not distribute cash to shareholders. Instead of paying dividends, the company retains all earnings—whether positive or negative—to reinvest into growth initiatives, specifically the advancement of its lead immunotherapy, Multikine, through clinical trials. The overall growth and income profile is characterized by a complete reliance on capital appreciation potential rather than dividend income, with growth metrics currently unquantifiable due to the absence of historical revenue and earnings data in the reporting period.